Introduction Breast cancer is one of the most common cancers among women. There are many different therapies for treating breast cancer that targeted therapy is one of them. Herceptin is a monoclonal antibody against Her2-neu receptor that is over expressed in some breast cancer cell lines that is used in targeted therapy. This drug is expensive, has lots of side effects, and has low efficiency. Immunotoxins are another kind of targeted therapy that results in the binding of a toxin to one of the immune systems components such as antibodies. In this study we introduce an immunotoxin consisting of a truncated pseudomonas exotoxin A conjugated to Herceptin antibody in order to improve the efficiency of the Herceptin drug.
